In addition, CCL2 also synergetic with HGF/MET pathway to promote the progression and metabolic reprogramming of breast cancer, and the combination of CCR2 knockout and MET inhibitor meritinib can more effectively inhibit tumor growth and stromal response (230). The gene discussed is CCL2; the disease is breast carcinoma.